



**EURO-ATAXIA
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30th August 2023**

Euro-ataxia Annual Report 2022-23

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 30 August 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). The Trustees can confirm that the activities of Euro-ataxia are lawful.

Objectives and Activities

The objects of Euro-ataxia are “to relieve those persons affected by ataxia”.

Euro-ataxia is an international association whose member organisations work together to give people with ataxia as normal a life as possible. We do this by building a strong organisation that represents people with hereditary ataxia throughout Europe.

Public Benefit

In compliance with the Charities Act 2011 the trustees of Euro-ataxia have adopted the following statement on Public Benefit:

Euro-ataxia is an inclusive organisation which promotes the wellbeing of all of those affected by ataxia across Europe. We do this by

- Driving forward research and treatment of the ataxias.
- Encouraging the free flow of information between members on the latest research.
- Fostering and improving contacts between practitioners interested in the ataxias, and people with ataxia.
- Investigating social, political and cultural matters connected to the welfare of people with ataxia, and promoting and improving the exchange of this information.
- Promoting co-operation on an international level between national ataxia organisations.
- Raising awareness of ataxia among clinicians, scientists and society.

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

Membership as at 30th August 2023

- | | |
|---|----------------|
| • Association Belge de l'Ataxie de Friedreich (ABAF) | Belgium |
| • ADCA Vereniging Nederland | Netherlands |
| • Associação Portuguesa de Ataxias Hereditárias (APAHE) | Portugal |
| • Association Connaître les Syndromes Cérébelleux (CSC) | France |
| • Association for Families with Spinocerebellar Ataxia | Poland |
| • Association Française de l'Ataxie de Friedreich | France |
| • Associazione Italiana per la lotta alle Sindromi | Italy |
| • Ataxia Telangiectasia Society | United Kingdom |
| • Ataxia UK | United Kingdom |
| • Deutsche Heredo-Ataxie Gesellschaft e. V. | Germany |
| • Federación de Ataxias de España (FEDAES) | Spain |
| • Foreningen for ATAKSI HSP | Denmark |
| • Friedreich Ataxie Förderverein e.V. | Germany |
| • Hellenic Friedreich's Ataxia Association | Greece |

- The Israeli Machado Joseph Association Israel
- NASPA (Landsforeningen for spastisk paraparese og ataksi) Norway
- Spierziekten Vlaanderen Belgium
- Schweizerische Gesellschaft für Muskelkranke Switzerland
- Vereniging Spierziekten Nederland – Werkgroep Netherlands

Executive Committee

President Andreas Nadke, DHAG (Deutsche Heredo-Ataxie Gesellschaft)

Secretary General Sue Millman, Ataxia UK

Scientific Advisor Dr Julie Greenfield, Ataxia UK

Board Members:

Susie Norbury, Ataxia Telangiectasia Society

Madeleine Schmeder, AFAF (l'Association Francaise de l'Ataxie de Friedreich)

Bart-Jan Schuman, FAF (Friedreich Ataxie Förderverein e.V.)

Juan Carlos Baiges, FEDAES (Federación de Ataxias de España)

John Gerbild, Foreningen for ATAKSI HSP

Vasileios Karatzias, Hellenic Friedreich's Ataxia Association

Carlos Neves, APAHE - Associação Portuguesa de Ataxias Hereditárias

Tomer Hillel, Israeli Machado Joseph Association

Achievements and Performance

• Membership of European Organisations & Committees

Euro-ataxia was represented on several European Organisations & Committees as follows:

- Eurordis Vassilis Karatzias & John Gerbild
- European Federation of Neurological Associations John Gerbild

• Euro-ataxia Annual Meeting 2023

With the generous financial help of the European Union's Horizon 2020 research and innovation programme, and kindly supported by the Hellenic Friedreich's Ataxia Association, in May 2023 Euro-ataxia held its annual meeting as an in-person conference in Pieria, Greece.

It featured talks from academic researchers, pharma company representatives and patient representatives and others. Content included lay presentations from researchers and updates on the EFACTS and the TREAT-ARCA projects (see below). It was also an opportunity to hear about new activities from member groups, get an overview of Euro-ataxia's research activities and conduct the AGM.

• Supporting Research

Euro-ataxia members have taken part in the following Research Consortia to provide patient group representation and involvement in line with the [Euro-ataxia Patient Charter](#).

European SCA3/Machado Joseph disease initiative (ESMI)

The ESMI project continues. This consortium has successfully established the largest cohort of systematically characterised patients with SCA3 worldwide. The cohort consists of over 400 SCA3 mutation carriers (with the majority being people with SCA3 and a small proportion of pre-symptomatic individuals) and around 100 age-matched healthy control subjects. The consortium is also playing an important role in the development of biomarkers. This is an extremely useful resource for running trials in Europe. This project has been recruiting participants since 2017 and Julie Greenfield has continued to participate in the Steering Committee as a Euro-ataxia

representative. Since the EU JPND funding ended the Consortium has been successful in getting funding from pharma companies in order to continue some aspects of the study.

Progression chart of spastic ataxias (PROSPAX) project

The PROSPAX project, launched in June 2020, is a collaborative effort between neurologists across Europe, plus Canada. The project aims to study the progression of spastic ataxias over time, in a rigorous and harmonised way - from the clinical to the molecular level, including brain imaging, markers of progression and animal models. The project initially focuses on ARSACS and SPG7 but will establish a more general research framework that will be applicable to other spastic ataxias over time. Euro-ataxia has been involved in the project as an active partner representing European ataxia patients, with support from Ataxia UK and the German ataxia group DHAG. Andreas Nadke (DHAG) represents Euro-ataxia. There is a very active Patient Organisation Group which is leading a Work package working on creating a Patient Reported Outcome Measures by assembling surveys for distribution via patient groups, to collect information to be used in this study and in future trials. Euro-ataxia receives some funding for the work being done.

The third annual PROSPAX meeting was held in Turkey in June 2023. Updates were given on the different working packages of the project, including the PROSPAX natural history study; creating an app to measure SPG7 and ARSACS; and results from patient surveys on the frequency and impact of symptoms of ataxia and HSP.

The European Friedreich's ataxia Consortium for Translational Studies (EFACTS)

This is a study originally funded by the European Commission which is gathering vital information about the progression of Friedreich's ataxia (FA) which will provide a better knowledge of the prognosis and development of their condition. The purpose is to generate a large FA patient database, alongside an integrated clinical and natural history database; this will be linked to a biological samples repository. It also aims to define a panel of clinical assessment tools for use in future trials. Data from this study has resulted in useful publications and is also being used to plan clinical trials. Madeleine Schmeder (AFAF) and Barry Hunt (Ataxia UK) represented Euro-ataxia on the Steering Committee during the year.

Cerebellum and Emotional Networks (CEN)

The Cerebellum and Emotional Networks (CEN) is a Marie Skłodowska-Curie Innovative Training Network funded by the European Research Council investigating the brain circuits that underlie emotional behaviour. The project is creating a Virtual Institute of 7 European universities and 7 industry/charity partners, including Euro-ataxia. The consortium brings together researchers from across Europe to share and combine knowledge in the field of cerebellar research and in the field of anxiety disorders and the role of the cerebellum in the control of emotions. The knowledge gained will inform the development of new therapeutic strategies for individuals suffering from emotional disorders.

The Annual Conference 2023 took place in Essen, Germany at which Marion Nadke, President of the German Heredo-Ataxie Society (DHAG), and Andreas Nadke, President of Euro-ataxia, offered insights into the perspectives of people directly affected by cerebellar disorders in their presentations, powerfully demonstrating the impact of scientific advances and compassionate care on those affected and their families.

Designing a toolbox of paradigmatic treatments for a targeted molecular medicine approach to autosomal recessive ataxias - TREAT-ARCA

This project focuses on recessive ataxias and in particular ARSACS and ARCA2. It aims to design and test treatments, including gene therapy in animal model systems of ARSACS and ARCA2. It also aims to develop biomarkers. Andreas Nadke (DHAG) and Emily Cutting (Ataxia

UK) were the Euro-ataxia representatives on this project. Euro-ataxia is receiving some funding to support the work undertaken in this project.

Spinocerebellar ataxias: Advanced imaging with ultra-high field MRI (SCAIFIELD)

This project involves a European Consortium who are developing novel brain scanning biomarkers for spinocerebellar ataxias, using high-field MRI scanning technology. This project is a collaboration between researchers in Germany, Norway and Belgium and includes people with SCA1, SCA2, SCA3 and SCA6 with a focus on the most common (SCA3) and fastest progressing (SCA1). Participant recruitment started in 2022. Both symptomatic and pre-symptomatic subjects will be included. Cathalijne van-Doorne (ADCA-A Vereniging Nederland) was the Euro-ataxia representative on this project. It is due to complete in 2024.

EVIDENCE-RND: creating robust evidence for longitudinal progression changes and treatment effects in ultra-rare neurological disease

This project started during the year and is funded by the EU EJPRD call “Innovative Methods for Rare Diseases”. There is a scarcity of robust trial design and analysis methods in ultra-rare neurological diseases (RND) affecting small cohorts (< 50) or even single cases. The urgency to find solutions is accelerated as disease-modifying compounds are now on the horizon for a growing number of RNDs, yet methods to generate robust evidence for treatment effects are missing. EVIDENCE-RND will develop a toolbox of innovative statistical methodologies designed to fill this gap. Our methods toolbox will deliver: (i) an optimized clinically meaningful composite endpoint for RNDs, including methods to evaluate applicability across ultra-rare RND subpopulations; (ii) robust progression models, including prediction of individual disease trajectories and quantification of their uncertainty; (iii) pharmacometrics models to analyse treatment efficacy and guide trial design and treatment decisions even in n-of-1 studies; (iv) randomization-based inference models for valid and efficient RCTs in ultra-small cohorts. As showcase, they will be applied to autosomal-recessive cerebellar ataxias, leveraging registry datasets from major transatlantic consortia (PREPARE, PROSPAX, EUROSCA, ESMI), close communication with patient organisations (Euro-Ataxia) and industry trial expertise (Novartis, AstraZeneca). Continuous interaction with EMA and C-Path will ensure that the overall goal will be readily achieved: to provide EMA with proposals for optimized outcomes, trial designs, and innovative analyses, optimized to be as informative as possible to allow robust evidence in the smallest possible populations.

Ataxia Global Initiative

The Ataxia Global Initiative is a worldwide research platform that has the goal to facilitate the clinical development of therapies for ataxias. Euro-ataxia is a partner organization and has encouraged Euro-ataxia member groups to join.

Specifically, the Ataxia Global Initiative:

- promotes sharing of data and biomaterials,
- contributes to the definition of worldwide accepted common standards for clinical research and interventional trials,
- provides information that is relevant to prepare and conduct clinical trials,
- organises and hosts international meetings and conferences to update and educate the field on key issues,
- provides services that support trial readiness,
- offers training and education programmes, and provides information about clinical research to people with ataxia and the public.

For more information see: <https://ataxia-global-initiative.net>

Euro-ataxia has also continued to offer support to European networks of researchers applying for grants from European funding streams and has been a partner in two Consortia.

Financial Review

We achieved a surplus for the year of £9,448, and consequently increased the net assets from £5,084 to £14,532. Despite the challenging economic conditions, we are confident that we can continue to make further strides while continuing to live within our means, albeit at modest levels of activity.

We shall continue to keep the subscriptions levels under review, endeavour to get members to pay them on time, and seek to recruit new members.

In accordance with the trustees' reserves policy, we are seeking to build up unrestricted reserves to the level of six months unrestricted operating costs.

- **Risk Assessment**

The Trustees have identified the following risks to the charity

Level of Risk	Nature of Risk	Mitigation
High	The potential for European Union Institutions to take a negative view of a charity registered in the UK and for this to have a negative impact on income or activities.	The Trustees have now resolved to eliminate this risk by moving the registration of the charity to Germany. This is in progress.
Medium	Reduction in income & continuing deficit.	We have increased subscription levels from €1 to €2 per member with ataxia, capped at €700.
Low	Reduction of members	Euro-ataxia has retained its membership of 19 patient groups and will be increasing its activity to ensure its worth to the European ataxia community.

Structure, Governance and Management

Euro-ataxia is established as a charity registered with the Charity Commission number 1149330 and as a Limited Company number 8187765. Its founding documents are Articles of Association adopted in August 2012. Membership of Euro-ataxia is open to any organisations and individuals the Board decides to admit into membership. The charity holds an AGM annually. In between AGMs the charity is managed by Board Members who are elected annually at the AGM.

- **Annual General Meeting**

The AGM was held on Saturday 20th May 2023 in Greece with members present representing 9 member associations.

- Three Trustees were required to resign and were re-elected. (See table below)
- The meeting thanked Cathalijne van Doorne for her service in the post of President.

- **Directors and Trustees of the Charity and Limited Company**

Andreas Nadke	Deutsche Heredo Ataxie Gesellschaft	President	19/10/2021	Resigned as Trustee & Elected as President
Sue Millman	Ataxia UK	Company Secretary	27/06/2022	Re-elected as Trustee
Susie Norbury	Ataxia Telangiectasia Society	Treasurer	27/04/2022	Resigned as Trustee & elected as Treasurer
Madeleine Schmeder	Association Française de l'Ataxie de Friedreich	Trustee	10/11/2018	Elected as Trustee
Cathalijne Van Doorne	ADCA Vereniging Nederland	Trustee	19/10/21 27/06/22 20/05/2023	Resigned as President Re-elected as Trustee Resigned as Trustee
Juan-Carlos Baiges	Federación de Ataxias de España	Trustee	10/11/2018 20/05/2023	Elected as Trustee Re-elected as Trustee
John Gerbild	Foreningen for ATAKSI HSP	Trustee	27/06/2022	Re-elected as Trustee
Vassilis Karatzias	Hellenic Association	Trustee	27/06/2022	Elected as Trustee
Carlos Neves	Associação Portuguesa de Ataxias Hereditárias	Trustee	20/05/2023	Elected as Trustee
Bart-Jan Schuman	Friedreich AtaxieFördervereine.V.	Trustee	10/11/2018 20/05/2023	Elected as Trustee Re-elected as Trustee
Tomer Hillal	Israeli Machado Joseph Association	Trustee	10/11/2018	Elected as Trustee

- **Advisors to Euro-ataxia**

Research

Dr Julie Greenfield

Head of Research Ataxia UK

Professor Barry Hunt

Scientific Advisor Ataxia UK

Finance

Stephanie Lawrence

Head of Finance Ataxia UK

- **Reference and Administrative Details**

Registered Company Number: 08187765 (England and Wales)

Registered Charity Number: 1149330

Registered Office 12 Broadbent Close Highgate, London N65JW

Email address: smillman@ataxia.org.uk

Independent Examiner: Shaw Gibbs Chartered Accountants, Wey Court West, Union Road, Farnham, Surrey. GU9 7PT

Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature




Full name

Andreas Nadke
President

Susan Millman
Secretary

Date

18th October 2024

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF EURO-ATAXIA

Independent examiner's report to the trustees of Euro-Ataxia ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 August 2023

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102)).
5. I can confirm that the Company's activities are lawful.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Date: 18th October 2024

D.G Hooper FCA Chartered
Accountant
Shaw Gibbs Chartered Accountants
Wey Court West,
Union Road,
Farnham, Surrey.
GU9 7PT

Euro-Ataxia
Statement of Financial Activities
For the Year Ended 30 August 2023

	Notes	Unrestricted Funds 2023 £	Restricted Funds 2023 £	Total 2023 £	Total 2022 £
INCOME AND ENDOWMENTS FROM					
Donations	2	3,663	-	3,663	3,693
Grants	2	16,692	-	16,692	4,611
Total		20,355		20,355	8,304
EXPENDITURE ON					
Raising funds		0	0	0	0
Charitable activities					
Charitable expenditure		9,743		9,743	4,703
Other		1,164		1,164	1,135
Total	4	10,907		10,907	5,838
NET INCOME	3	9,448		9,448	2,465
RECONCILIATION OF FUNDS					
Total funds brought forward		5,084		5,084	2,619
TOTAL FUNDS CARRIED FORWARD		14,532		14,532	5,084

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

Euro-Ataxia
Balance Sheet
For the Year Ended 30 August 2023

		Unrestricted	Restricted	2023 Total	2022 Total
	Notes	Fund £	Fund £	Funds £	Funds £
Fixed Assets					
Intangible assets	5				
Current Assets					
Debtors	6	4,414		4,414	3,682
Cash at bank		29,851		29,851	19,337
		34,265		34,265	23,019
CREDITORS				-	
Amounts falling due within one year	7	<u>(4,290)</u>		<u>(4,290)</u>	<u>(1,792)</u>
NET CURRENT ASSETS		<u>29,975</u>		<u>29,975</u>	<u>21,227</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		29,975		29,975	21,227
CREDITORS					
Amounts falling due after more than one year	8	(15,443)		(15,443)	(16,143)
NET ASSETS		14,532		14,532	5,084
FUNDS	10				
Unrestricted funds				<u>14,532</u>	<u>5,084</u>
TOTAL FUNDS				<u>14,532</u>	<u>5,084</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 August 2023

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2022 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 29 August 2024 and were signed on its behalf by:

Susan Millman

EURO-ATAXIA
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 30 August 2023

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received, and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings, they have been allocated to activities on a basis consistent with the use of resources.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

EURO-ATAXIA
NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 30 August 2023

2 DONATIONS & GRANTS

	Unrestricted		Restricted		Total 2023 £	Total 2022 £
	Funds		Funds			
	2023 £	2023 £	2023 £	2022 £		
Donations and grants	3,663				3,663	3,693
Research grant	16,692				16,692	4,611
	<u>20,355</u>				<u>20,355</u>	<u>8,304</u>
For the year ended 31 August 2022	<u>3,693</u>		<u>4,611</u>			<u>8,304</u>

3 NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2023 £	2022 £
Independent examiners' fees	780	619

4 TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 30 August 2023 nor for the year ended 31 August 2022

Trustees' Expenses

There were no trustees' expenses paid for the year ended 30 August 2023 nor for the year ended 31 August 2022

5 INTANGIBLE FIXED ASSETS

	£
Cost	
At 1 September 2022 and 30 August 2023	<u>6,000</u>
Amortisation and impairment	
At 1 September 2022	6,000
Amortisation charged for the year	0
	<u>6,000</u>
At 30 August 2023	<u>6,000</u>
Carrying amount	
At 30 August 2023	<u>0</u>
At 31 August 2022	<u>0</u>

EURO-ATAXIA
NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 30 August 2023

6 DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR:

	2023	2022
	£	£
Subscription and other debtors	4,414	3,682
	<u>4,414</u>	<u>3,682</u>

7 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR:

	2023	2022
	£	£
Accruals	4,290	1,792
	<u>4,290</u>	<u>1,792</u>

8 CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR:

	2023	2022
	£	£
Loan Ataxia UK	15,443	16,143
	<u>15,443</u>	<u>16,143</u>

The loan is from Ataxia UK and has no fixed repayment terms.

9 RELATED PARTY DISCLOSURES

Ms. S. Millman, a trustee, is also the Chief Executive of Ataxia UK.

EURO-ATAxia
NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 30 August 2023

10 MOVEMENT IN FUNDS

	At 01.09.22 £	Net Movement in funds £	At 30.08.23 £
General fund	5,084	9,448	14,532
TOTAL FUNDS	5,084	9,448	14,532

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended in funds £	Movement in funds £
General Fund	20,355	(10,907)	9,448
TOTAL FUNDS	20,647	(10,907)	9,448

Comparatives for movement in funds

	At 01.09.21 £	Net Movement in funds £	At 31.08.22 £
General fund	2,619	2,465	5,084
	<u>2,619</u>	<u>2,465</u>	<u>5,084</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended in funds £	Movement in funds £
General Fund	8,304	(5,838)	2,465
TOTAL FUNDS	8,304	(5,838)	2,465

A current year 12 months and prior year 12 months combined position is as follows:

	At 01.09.21 £	Net Movement in funds £	At 30.08.23 £
General fund	2,619	11,913	14,532
	<u>2,619</u>	<u>11,913</u>	<u>14,532</u>

A current year 12 months and prior year 12 months combined *net* movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended in funds £	Movement in funds £
General Fund	28,659	(16,746)	11,913
TOTAL FUNDS	28,659	(16,746)	11,913

There are currently no restricted funds.

Euro-Ataxia
DETAILED STATEMENT OF FINANCIAL ACTIVITIES
For the Year Ended 30 August 2023

	2023	2022
	£	£
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	11,322	8
membership subscriptions	<u>3,663</u>	<u>3,685</u>
	14,985	3,693
Other trading activities		
Research grant	<u>5,370</u>	<u>4,611</u>
	<u>5,370</u>	<u>4,611</u>
Total Incoming resources	20,355	8,304
EXPENDITURE		
Support Costs		
Management		
Website costs	0	93
Research Services	900	4,611
Sundries	138	141
Conference Costs	8,843	0
Subscriptions	<u>140</u>	<u>172</u>
Total	10,021	5,016
Finance		
Bank charges	94	88
Other		
Loss on exchange	32	115
Governance costs		
Independent examiners' fees	760	619
Total resources expended	<u>10,907</u>	<u>5,838</u>
NET INCOME	<u>9,448</u>	<u>2,465</u>

This page does not form part of the statutory financial statements.